Host Response Mediators in Coronavirus (COVID-19) Infection
ARBS CORONA I
1 other identifier
observational
500
1 country
15
Brief Summary
The coronavirus (COVID-19) pandemic continues to grow exponentially. Angiotensin II levels are increased in human influenza and are associated with influenza viral load, disease progression and mortality. Preliminary data shows angiotensin II receptor blockers (ARBs) limits lung injury in murine influenza H7N9, as well as viral titre and RNA. ARBs could limit viral titre and organ injury in COVID-19. We will therefore collect clinical chart data and test angiotensin II levels of patients who are admitted to ICU with COVID-19 to determine whether there is a correlation between taking ARBs and clinical outcomes in these patients. Other blood biomarkers and clinical risk factors for COVID-19 have come to light in recent weeks. We include these in our observational analysis to help generate an understanding of COVID-19 presentation and blood biomarker characterization of disease.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Mar 2020
Typical duration for all trials
15 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
March 17, 2020
CompletedFirst Submitted
Initial submission to the registry
August 11, 2020
CompletedFirst Posted
Study publicly available on registry
August 12, 2020
CompletedPrimary Completion
Last participant's last visit for primary outcome
June 30, 2021
CompletedStudy Completion
Last participant's last visit for all outcomes
June 30, 2022
CompletedAugust 12, 2020
August 1, 2020
1.3 years
August 11, 2020
August 11, 2020
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
COVID-19 WHO ordinal scale
14 days
Secondary Outcomes (4)
Organ Dysfunction
14 days
28-day mortality
29 days or less (may be discharged from critical care before day 28)
Hospital/ICU length of stay
29 days or less (may be discharged before day 28)
ICU admission
29 days or less (may be discharged from critical care before day 28)
Study Arms (4)
COVID-19 Patients on ARBs
This is an observational cohort study. Those who have COVID-19 in hospital and are on Angiotensin Receptor Blockers will be included in this cohort.
COVID-19 Patients on ACE inhibitors
This is an observational cohort study. Those who have COVID-19 in hospital and are on Angiotensin-Converting Enzyme inhibitors will be included in this cohort.
COVID-19 Patients on ARBs or ACE inhibitors
This is an observational cohort study. Those who have COVID-19 in hospital and are on ARBs or ACEi's will be included in this cohort.
COVID-19 Patients not on ARBs or ACE inhibitors
This is an observational cohort study. Those who have COVID-19 in hospital and are not on ARBs or ACEi's will be included in this cohort.
Interventions
This is an observational study only.
Eligibility Criteria
Adult hospitalized patients with confirmed COVID-19
You may qualify if:
- Individuals over 18 years of age who have confirmed COVID-19 infection (according to local hospital or provincial laboratories clinically approved laboratory testing for COVID-19).
You may not qualify if:
- None
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- University of British Columbialead
- Canadian Institutes of Health Research (CIHR)collaborator
- British Columbia Centre for Disease Controlcollaborator
- McGill University Health Centre/Research Institute of the McGill University Health Centrecollaborator
- University of Torontocollaborator
- University of Ottawacollaborator
- University of Calgarycollaborator
- University of Albertacollaborator
- University of Victoriacollaborator
- Wuhan Universitycollaborator
- Peking Union Medical Collegecollaborator
- University of Pennsylvaniacollaborator
Study Sites (15)
University of Calgary - Foothills
Calgary, Alberta, Canada
Stollery Children's Hospital
Edmonton, Alberta, Canada
University of Alberta
Edmonton, Alberta, Canada
Surrey Memorial Hospital
Surrey, British Columbia, Canada
St Pauls Hospital
Vancouver, British Columbia, V6Z1Y6, Canada
Vancouver General Hospital
Vancouver, British Columbia, Canada
William Osler Health System
Brampton, Ontario, Canada
Queens University
Kingston, Ontario, Canada
Humber River Hospital
North York, Ontario, Canada
Mount Sinai Hospital
Toronto, Ontario, Canada
St Michael's Hospital
Toronto, Ontario, Canada
Sunnybrook Hospital
Toronto, Ontario, Canada
Jewish General Hospital
Montreal, Quebec, Canada
McGill University Health Center
Montreal, Quebec, Canada
Université de Sherbrooke
Sherbrooke, Quebec, Canada
Related Publications (2)
Lee T, Cheng MP, Vinh DC, Lee TC, Tran KC, Winston BW, Sweet D, Boyd JH, Walley KR, Haljan G, McGeer A, Lamontagne F, Fowler R, Maslove D, Singer J, Patrick DM, Marshall JC, Burns KD, Murthy S, Mann PK, Hernandez G, Donohoe K, Rocheleau G, Russell JA; ARBs CORONA I study investigators. Organ dysfunction and death in patients admitted to hospital with COVID-19 in pandemic waves 1 to 3 in British Columbia, Ontario and Quebec, Canada: a cohort study. CMAJ Open. 2022 Apr 19;10(2):E379-E389. doi: 10.9778/cmajo.20210216. Print 2022 Apr-Jun.
PMID: 35440485DERIVEDRussell JA, Marshall JC, Slutsky A, Murthy S, Sweet D, Lee T, Singer J, Patrick DM, Du B, Peng Z, Cheng M, Burns KD, Harhay MO. Study protocol for a multicentre, prospective cohort study of the association of angiotensin II type 1 receptor blockers on outcomes of coronavirus infection. BMJ Open. 2020 Dec 7;10(12):e040768. doi: 10.1136/bmjopen-2020-040768.
PMID: 33293316DERIVED
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
James A Russell, MD
St Paul's Hospital, Center for Heart and Lung Innovation
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- OTHER
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Study-Wide Principal Investigator
Study Record Dates
First Submitted
August 11, 2020
First Posted
August 12, 2020
Study Start
March 17, 2020
Primary Completion
June 30, 2021
Study Completion
June 30, 2022
Last Updated
August 12, 2020
Record last verified: 2020-08